NELFCD and cancer: Because each malignant tumor is unique, with its own set of mutations and dysregulated genes, most established cancer cell lines can be expected to behave somewhat differently with individual treatments; nonetheless, we found that sunitinib worked very well when combined with Th1 cytokines in a set of phenotypically diverse lines which included hormone receptor-positive, HER-2-positive, and triple-negative cells.